Hyperglycemia newly detected by glycated hemoglobin affects all-cause mortality in coronary artery disease patients: a retrospective cohort study

Wei, Wen; Guo, Dachuan; Xu, Xinghao; Xu, Qingbo; Li, Shanggang; Li, Yuqi; Liu, Jin; Liu, Yong; Tu, Mei; Chen, Kaihong; Chen, Hong; Chen, Shiqun

doi:10.1016/j.diabres.2022.110053

Cited by 4 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several clinical observational studies demonstrate that hyperglycaemia is associated with poor outcomes in patients with obstructive CAD [31,32]. On the other hand, patients with angiographically normal coronary arteries with slow flow represent a population with a potentially different etiology and pathophysiology.…”

Section: Discussionmentioning

confidence: 99%

Predictors of Long-Term Mortality in Patients with Stable Angina Pectoris and Coronary Slow Flow

Aksoy

Öz

et al. 2023

Medicina

View full text Add to dashboard Cite

Background and Objectives: Coronary slow flow (CSF) is an angiographic phenomenon characterized by the slow progression of an injected contrast agent during diagnostic coronary angiography in the absence of significant stenosis. Although CSF is a common angiographic finding, the long-term outcomes and mortality rates are still unknown. This study aimed to investigate the underlying causes of mortality over a 10-year period in patients diagnosed with stable angina pectoris (SAP) and CSF. Materials and Methods: This study included patients with SAP who underwent coronary angiography from 1 January 2012 to 31 December 2012. All patients displayed CSF despite having angiographically normal coronary arteries. Hypertension (HT), diabetes mellitus (DM), hyperlipidaemia, medication compliance, comorbidities, and laboratory data were recorded at the time of angiography. Thrombolysis in myocardial infarction (TIMI) frame count (TFC) was calculated for each patient. The cardiovascular (CV) and non-CV causes of long-term mortality were assessed. Results: A total of 137 patients with CSF (93 males; mean age: 52.2 ± 9.36 years) were included in this study. Twenty-one patients (15.3%) died within 10 years of follow-up. Nine (7.2%) and 12 (9.4%) patients died of non-CV and CV causes, respectively. Total mortality in patients with CSF was associated with age, HT, discontinuation of medications, and high-density lipoprotein cholesterol (HDL-C) levels. The mean TFC was associated with CV mortality. Conclusion: Patients with CSF exhibited a notable increase in cardiovascular-related and overall mortality rates after 10 years of follow-up. HT, discontinuation of medications, HDL-C levels, and mean TFC were associated with mortality in patients with CSF.

show abstract

Section: Discussionmentioning

confidence: 99%

Predictors of Long-Term Mortality in Patients with Stable Angina Pectoris and Coronary Slow Flow

Aksoy

Öz

et al. 2023

Medicina

View full text Add to dashboard Cite

show abstract

“…Hyperglycaemia and hyperlipidemia are independent risk factors for CVD. The microvascular, macrovascular, and myocardial tissues of the human body will be harmed by long-term hyperglycemia, which will also hasten the development of cardiovascular disorders such as atherosclerosis, acute myocardial infarction, diabetic cardiomyopathy, and heart failure ( Withaar et al, 2021 ; Paolisso et al, 2022 ; Rampin et al, 2022 ; Wei et al, 2022 ; Li et al, 2023a ). Atherosclerosis is known to be facilitated by hyperlipidemia.…”

Section: Mechanism Of Action Of Scu On Cvdmentioning

confidence: 99%

Effects of scutellarin on the mechanism of cardiovascular diseases: a review

Zhang,

Yin,

Wang

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Cardiovascular diseases represent a significant worldwide problem, jeopardizing individuals’ physical and mental wellbeing as well as their quality of life as a result of their widespread incidence and fatality. With the aging society, the occurrence of Cardiovascular diseases is progressively rising each year. However, although drugs developed for treating Cardiovascular diseases have clear targets and proven efficacy, they still carry certain toxic and side effect risks. Therefore, finding safe, effective, and practical treatment options is crucial. Scutellarin is the primary constituent of Erigeron breviscapus (Vant.) Hand-Mazz. This article aims to establish a theoretical foundation for the creation and use of secure, productive, and logical medications for Scutellarin in curing heart-related illnesses. Additionally, the examination and analysis of the signal pathway and its associated mechanisms with regard to the employment of SCU in treating heart diseases will impart innovative resolving concepts for the treatment and prevention of Cardiovascular diseases.

show abstract

“…7 Prediabetes, as an antecedent of diabetes, is likewise associated with adverse events in the general population 8 and in those who have underlying cardiovascular disease. 9,10 The potential added risk incurred by prediabetes in patients receiving ACT remains unexplored. The objective of this study was to elucidate the association of baseline glycemic status (both prediabetes and diabetes) with longterm prognosis in patients who are prescribed ACT.…”

Section: Introductionmentioning

confidence: 99%

“…Type 2 diabetes is an established risk factor in the development of HF and mortality for patients with cancer who are prescribed ACT 5,6 and is currently cited as a moderate risk factor for AIC in the European Society of Cardiology guidelines on cardio‐oncology 7 . Prediabetes, as an antecedent of diabetes, is likewise associated with adverse events in the general population 8 and in those who have underlying cardiovascular disease 9,10 . The potential added risk incurred by prediabetes in patients receiving ACT remains unexplored.…”

Section: Introductionmentioning

confidence: 99%

Prediabetes is associated with increased cardiac events in patients with cancer who are prescribed anthracyclines

Cheang,

Zhu,

Huang

et al. 2024

Cancer

View full text Add to dashboard Cite

BackgroundPrediabetes, which is a precedent of overt diabetes, is a known risk factor for adverse cardiovascular outcomes. Its impact on adverse cardiovascular outcomes in patients with cancer who are prescribed anthracycline‐containing chemotherapy (ACT) is uncertain. The objective of this study was to evaluate the association of prediabetes with cardiovascular events in patients with cancer who are prescribed ACT.MethodsThe authors identified patients with cancer who received ACT from 2000 to 2019 from Clinical Data Analysis Reporting System of Hong Kong. Patients were divided into diabetes, prediabetes, and normoglycemia groups based on their baseline glycemic profile. The Primary outcome, a major adverse cardiovascular event (MACE), was the composite event of hospitalization for heart failure and cardiovascular death.ResultsAmong 12,649 patients at baseline, 3997 had prediabetes, and 5622 had diabetes. Over median follow‐up of 8.7 years, the incidence of MACE was 211 (7.0%) in the normoglycemia group, 358 (9.0%) in the prediabetes group, and 728 (12.9%) in the diabetes group. Compared with normoglycemia, prediabetes (adjusted hazard ratio [HR], 1.20; 95% confidence interval [CI], 1.01–1.43) and diabetes (adjusted HR, 1.46; 95% CI, 1.24–1.70) were associated with an increased risk of MACE. In the prediabetes group, 475 patients (18%) progressed to overt diabetes and exhibited a greater risk of MACE (adjusted HR, 1.76; 95% CI, 1.31–2.36) compared with patients who remained prediabetic.ConclusionsIn patients with cancer who received ACT, those who had prediabetes at baseline and those who progressed to diabetes at follow‐up had an increased risk of MACE. The optimization of cardiovascular risk factor management, including prediabetes, should be considered in patients with cancer who are treated before and during ACT to reduce cardiovascular risk.Plain Language Summary Patients with cancer who have preexisting diabetes have a higher risk of cardiovascular events, and prediabetes is often overlooked. In this study of 12,649 patients with cancer identified in the Clinical Data Analysis Reporting System of Hong Kong who were receiving treatment with anthracycline drugs, prediabetes was correlated with increased deaths from cardiovascular disease and/or hospitalizations for heart failure. Patients who progressed from prediabetes to diabetes within 2 years had an increased risk of combined hospitalization for heart failure and death from cardiovascular disease. These findings indicate the importance of paying greater attention to cardiovascular risk factors, including how prediabetes is managed, in patients who have cancer and are receiving chemotherapy with anthracyclines, emphasizing the need for surveillance, follow‐up strategies, and consideration of prediabetes management in cancer care.

show abstract

Hyperglycemia newly detected by glycated hemoglobin affects all-cause mortality in coronary artery disease patients: a retrospective cohort study

Cited by 4 publications

References 22 publications

Predictors of Long-Term Mortality in Patients with Stable Angina Pectoris and Coronary Slow Flow

Predictors of Long-Term Mortality in Patients with Stable Angina Pectoris and Coronary Slow Flow

Effects of scutellarin on the mechanism of cardiovascular diseases: a review

Prediabetes is associated with increased cardiac events in patients with cancer who are prescribed anthracyclines

Contact Info

Product

Resources

About